Asia-Pacific Bladder Cancer Therapeutics Market estimated to grow wit Asia-Pacific Bladder Cancer Therapeutics Market es | Page 6

8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Sanofi S.A. (France)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Novartis AG (Switzerland)
9.3 Pfizer Inc. (U.S.)
9.4 GlaxoSmithKline plc (U.K.)
9.5 Eli Lilly and Company (U.S.)
9.6 AstraZeneca plc (U.K.)
9.7 Bristol-Myers Squibb (U.S.)
9.9 F. Hoffmann-La Roche Ltd. (Switzerland)
9.10 Celgene Corporation (U.S.)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities